Advertisement

Antibiotic Therapy

  • Douglas Jacobstein
  • Howard Kader

Keywords

Ulcerative Colitis Crohn Disease Postoperative Recurrence Perianal Fistula Active Ulcerative Colitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sartor RB. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol 1997;92:5S–11S.PubMedGoogle Scholar
  2. 2.
    Rutgeerts P, Goboes K, Peeters M, et al. Effect of faecal stream diversion on recurrence of Crohn disease in the neoterminal ileum. Lancet 1991;338:771–74.PubMedCrossRefGoogle Scholar
  3. 3.
    Perencevich M and Burakoff R. Use of antibiotics in the treatment of inflammatory bowel disease. Inflamm Bowel Dis 2006;12:651–664.PubMedCrossRefGoogle Scholar
  4. 4.
    Ursing B, Alm, T, Barany F, et al. Comparative study of metronidazole and sulfasalazine for active Crohn disease: the cooperative Crohn disease study in Sweden. Gastroenterology 1982;83:550–562.PubMedGoogle Scholar
  5. 5.
    Rutgeerts P, Hile M, Geboes K, et al. Controlled trial of metronidazole for prevention of Crohn recurrence after ileal resection. Gastroenterology 1995;108:1617–21.PubMedCrossRefGoogle Scholar
  6. 6.
    Hildebrand H, Berg NO, Hoevels J, et al. Treatment of Crohn disease with metronidazole in childhood and adolescence. Gastroenterol Clin Biol 1980;4:19–25.PubMedGoogle Scholar
  7. 7.
    Ursing B and Kamme C. Metronidazole for Crohn disease. Lancet 1975;1:775–777.CrossRefGoogle Scholar
  8. 8.
    Sutherland L, Singleton J, Sessions J, et al. Double-blind placebo controlled trial of metronidazole in Crohn disease. Gut 1991;32:1071–1075.PubMedCrossRefGoogle Scholar
  9. 9.
    Colombel JF, Lemann M, Cassagnou M, et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn disease. Am J Gastroenterol 1999;94:674–678.PubMedCrossRefGoogle Scholar
  10. 10.
    Arnold GL, Beaves MR, Pryjdun VO, et al. Preliminary study of ciprofloxacin in active Crohn disease. Inflamm Bowel Dis 2002;8:10–15.PubMedCrossRefGoogle Scholar
  11. 11.
    Greenbloom SL, Steinhart AH, Greenberg GR. Combination ciprofloxacin and metronidazole for active Crohn disease. Can J Gastroenterol 1998;12:53–56.PubMedGoogle Scholar
  12. 12.
    Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996;91:328–332.PubMedGoogle Scholar
  13. 13.
    Prantera C, Berto E, Scribano ML, et al. Use of antibiotics in the treatment of active Crohn disease: experience with metronidazole and ciprofloxacin. Ital J Gastroenterol Hepatol 1998;30:602–606.PubMedGoogle Scholar
  14. 14.
    Schwartz DA, Pemberton JH, Sandborn WJ. Diagnosis and treatment of perianal fistulas in Crohn disease. Ann Intern Med 2001;135:906–18.PubMedGoogle Scholar
  15. 15.
    Allan R and Cooke WT. Evaluation of metronidazole in the management of Crohn disease. Gut 1977;18:A422.Google Scholar
  16. 16.
    Bernstein LH, Frank MS, Brandt LJ, et al. Healing of perianal Crohn disease with metronidazole. Gastroenterology 1980;79:357–365.PubMedGoogle Scholar
  17. 17.
    Brandt LJ, Bernstein LH, Boley SJ, et al. Metronidazole therapy for perianal Crohn disease: a follow-up study. Gastroenterology 1982;83:383–387.PubMedGoogle Scholar
  18. 18.
    Dejaco C, Harrer M, Waldhoer T, et al. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn disease. Aliment Pharmacol Ther 2003;18:1113–1120.PubMedCrossRefGoogle Scholar
  19. 19.
    West RL, Van Der Woude CJ, Hansen BE, et al. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn disease with infliximab: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2004;20:1329–1336.PubMedCrossRefGoogle Scholar
  20. 20.
    Baldassano RN, Han PD, Jeshion WC, et al. Pediatric Crohn disease: Risk factors for postoperative recurrence. Am J Gastroenterol 2001;96:2169–2176.PubMedCrossRefGoogle Scholar
  21. 21.
    Penner RM, Madsen KL, Fedorak RN. Postoperative Crohn disease. Inflamm Bowel Dis 2005;11:765–777.PubMedCrossRefGoogle Scholar
  22. 22.
    D’Haens GR, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn disease caused by infusion of Intestinal contents in excluded ileum. Gastroenterology 1998;114:262–267.PubMedCrossRefGoogle Scholar
  23. 23.
    Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn disease recurrence after ileal resection. Gastroenterology 1995;108:1617–1621.PubMedCrossRefGoogle Scholar
  24. 24.
    Rutgeerts P, Van Assche G, Vermeire S, et al. Ornidazole for prophylaxis of postoperative Crohn disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2005;128:856–861.PubMedCrossRefGoogle Scholar
  25. 25.
    Dickinson RJ, O’Connor HJ, Pinder I, et al. Double-blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut 1985;26:1380–84.PubMedCrossRefGoogle Scholar
  26. 26.
    Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as adjunct to corticosteroids in severe ulcerative colitis. Gut 1986;27:1210–12.PubMedCrossRefGoogle Scholar
  27. 27.
    Mantzaris GJ, Archavlis E, Christoforidis P, Kourtessas D, Amberiadis P, Florakis N, Petraki K, Spiliadi C, Triantafyllou G. A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. Am J Gastroenterol 1997;92:454–56.PubMedGoogle Scholar
  28. 28.
    Mantzaris GJ, Archavlis E, Christoforidis P, Kourtessas D, Amberiadis P, Florakis N, Petraki K, Spiliadi C, Triantafyllou G. A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. Am J Gastroenterol 1997;92:454–56.PubMedGoogle Scholar
  29. 29.
    Turunen UM, Farkkila MA, Hakala K, Seppala K, Sivonen A, Ogren M, Vuoristo M, Valtonen VV, Miettinen TA. Long-term treatment of ulcerative colitis with ciprofloxacin: A prospective, double-bind, placebo-controlled study. Gastroenterology 1998;115:1072–78.PubMedCrossRefGoogle Scholar
  30. 30.
    Gilat T, Suissa A, Leichtman G, et al. A comparative study of metronidazole and sulfasalazine in active, not severe, ulcerative colitis. J Clin Gastroenterol 1987;9:415–417.PubMedCrossRefGoogle Scholar
  31. 31.
    Burke DA, Axon AT, Clayden SA, et al. The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther 1990;4:123–129.PubMedCrossRefGoogle Scholar
  32. 32.
    Lobo AJ, Burke DA, Sobala GM, et al. Oral tobramycin in ulcerative colitis: effect on maintenance of remission. Aliment Pharmacol Ther 1993;7:155–158.PubMedCrossRefGoogle Scholar
  33. 33.
    Mantzaris GJ, Hatzis A, Kontogiannis P, et al. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol 1994;89:43–46.PubMedGoogle Scholar
  34. 34.
    Ohkusa T, Nomura T, Terai T, et al. Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: a randomized, controlled pilot trial with long-term follow-up. Scand J Gastroenterol 2005;40:1334–1342.PubMedCrossRefGoogle Scholar
  35. 35.
    Shafran I and Johnson LK. An open-label evaluation of rifaximin in the treatment of active Crohn disease. Cur Med Res Opin 2005;21:1165–69.CrossRefGoogle Scholar
  36. 36.
    Kornbluth A, Hunt M, George J, et al. Efficacy and safety of rifaximin in the treatment of mild-moderate Crohn disease: results of an open-label pilot study. Gastroenterology 2005;128:A579.Google Scholar
  37. 37.
    Campieri M, Rizzello F, Venturi A, Poggioli G, Ugolini F, Helwig U, Amadini C, Romboli E, Gionchetti P. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn disease: A randomized controlled study versus mesalazine. Gastroenterology 2000;118(suppl 1):A781.CrossRefGoogle Scholar
  38. 38.
    Gionchetti P, Rizzello F, Ferrieri A, Venturi A, Brignola C, Ferretti M, Peruzzo S, Miglioli M, Campieri M. Rifaximin in patients with moderate to severe ulcerative colitis refractory to steroid-treatment: A double-blind, placebo-controlled trial. Dig Dis Sci 1999;44:1220–21.PubMedCrossRefGoogle Scholar
  39. 39.
    Lukas M, Konecny M, Zboril V. Rifaximin in patients with mild to moderate activity of ulcerative colitis: An open label study. Gastroenterology 2002;122:A434.Google Scholar
  40. 40.
    Guslandi M, Giolla P, Testoni PA. Corticosteroid-sparing effect of Rifaximin, a nonabsorbable oral antibiotic, in active ulcerative colitis: preliminary clinical experience. Current Therapeutic Research 2004;65(3):292–96.CrossRefGoogle Scholar
  41. 41.
    Kornbluth, A, Hunt M, George J, Rochester J, Fried-Boxt E, Legnani P. An open label pilot trial of Rifaximin in the treatment of patients with refractory pouchitis. Gastroenterology 2006;130:A-658.Google Scholar
  42. 42.
    Gionchetti P, Rizzello F, Venturi A, Ugolini F, Rosi M, Brigidi P, Johansson R, Ferrieri A, Poggioli G, Campieri M. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther 1999;13:713–18.PubMedCrossRefGoogle Scholar
  43. 43.
    Duffy LF, Daum F, Fisher SE, et al. Peripheral neuropathy in Crohn disease patients treated with metronidazole. Gastroenterology 1985;88:681–84.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Douglas Jacobstein
    • 1
  • Howard Kader
  1. 1.Division of Pediatric GastroenterologySinai Hospital of BaltimoreSuite 407,. Baltimore

Personalised recommendations